A recently published study of patients with NSCLC on anti-PD-1 therapy found that those who responded to treatment had significantly higher percentages of effector CD4+ T cells (CD62low) prior to treatment initiation (p < 0.0001). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.